Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyRegional therapyVisceral SurgeryDiseaseBile Duct CarcinomaColon CancerEsophageal CancerGastric CancerPeritoneal Carcinomatosis, SecondaryRectal CancerTumor Biomarker DefinedSubgroupAdenocarcinoma of the esophagogastric junction (AEG)BRAF V600E mutationHER2+KRAS/NRAS WTKRAS G12C-MutationMismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)POLE/POLD1 mutationICD10C15.-C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C20C24.-C24.0C24.1C24.8C24.9C78.6MeSHAppendiceal NeoplasmsColonic NeoplasmsColorectal NeoplasmsCommon Bile Duct NeoplasmsEsophageal NeoplasmsPeritoneal NeoplasmsRectal NeoplasmsStomach NeoplasmsSequenceAIO (CFOL500/FU1500)/IRIN80/CETU(400/250), colorect. Ca, C1 (PID485) -|- AIO (CFOL500/FU1500)/IRIN80/CETU250, C2+ (PID486)AIO KRK-0104: CETU(400/250)/CAPE800/IRIN200, colorect. Ca, C1 (PID1818) -|- CETU250/CAPE800/IRIN200, C2+ (PID1819)AIO KRK-0104: CETU(400/250)/CAPE1000/OXAL130, colorect. Ca, C1 (PID1820) -|- CETU250/CAPE1000/OXAL130, C2+ (PID1821)Alliance A021502; ATOMIC: mFOLFOX-6 (OXAL85/CFOL400/FU2400)/ATEZ840, adj., colorect. Ca, C1-12 (PID3003) -|- ATEZ840, adj., C13-25 (PID3004)ANCHOR CRC: ENCO300/BINI45/CETU(400/250), colorect. Ca, C1 (PID2464) -|- C2-7 (PID2465) -|- C8+ (PID2466)AtezoTRIBE: FOLFOXIRI (IRIN165/OXAL85/CFOL200/FU3200)/ATEZ840/BEVA5, colorect. Ca (PID2672) -|- FOLFOXIRI (IRIN165/OXAL85/CFOL200/FU3200)/ATEZ840/BEVA5 - ATEZ840/BEVA5/CFOL200/FU3200, colorect. (PID2673)BEACON: ENCO300/BINI45/CETU400, colorect. Ca, C1 (PID1406) -|- ENCO300/BINI45/CETU250, C2+ (PID1407)BEACON: ENCO300/CETU400, colorect. Ca, C1 (PID1605) -|- ENCO300/CETU250, C2+ (PID1606)CECOG: FOLFOX-6 (OXAL100/CFOL400/FU2400)/CETU(400/250), colorect. Ca, C1 (PID1114) -|- FOLFOX-6 (OXAL100/CFOL400/FU2400)/CETU250, C2+ (PID1178)CETU(400/250)/IRIN350, colorekt. Ca, C1 (PID425) -|- CETU250/IRIN350, C2+ (PID426)CETU400, colorect. Ca, C1 (PID423) -|- CETU250, C2+ (PID424)CheckMate-142: NIVO3/IPIL1, colorect. Ca, second line (PID1386) -|- NIVO240 (PID1234)FOLFIRI (IRIN180/CFOL400/FU2400)/CETU(400/250), colorect. Ca, C1 (PID441) -|- FOLFIRI (IRIN180/CFOL400/FU2400)/CETU250, C2+ (PID442)FOLFOX-4 (OXAL85/CFOL200/FU600)/CETU(400/250), colorect. Ca, C1 (PID451) -|- FOLFOX-4 (OXAL85/CFOL200/FU600)/CETU250, C2+ (PID452)FOLFOXIRI (OXAL85/IRIN180/CFOL200/FU24000)/CETU(400/250), kolorekt. Ca, C1 (PID687) -|- C2+ (PID688)FUFOX (OXAL50/CFOL500/FU2000)/CETU(400/250), colorect. Ca, C1 (PID483) -|- FUFOX (OXAL50/CFOL500/FU2000)/CETU250, C2+ (PID484)GERCOR VELVET: mFOLFOX-7 (OXAL100/CFOL400/FU3000)/AFLI4, colorect. Ca (PID1916) -|- CFOL400/FU3000 /AFLI4, maint. (PID1917)HERACLES: TRAS4/LAPA1000, colorect. Ca, C1 (PID72) -|- TRAS2/LAPA1000, C2+ (PID1155)KRYSTAL-1 (variant 1): ADAG600/CETU400, colorect. Ca, C1 (PID2548) -|- ADAG600/CETU500, var. 1, C2+ (PID2602)KRYSTAL-1: ADAG600/CETU400, colorect. Ca, C1 (PID2548) -|- ADAG600/CETU250, C2+ (PID2549)mFOLFOX-6 (OXAL85/CFOL350/FU2400), Colon Ca, perioperative (PID2257).mFOLFOX-6 (OXAL85/CFOL400/FU2400)/CETU(400/250), colorect. Ca, C1 (PID1112) -|- mFOLFOX-6 (OXAL85/CFOL400/FU2400)/CETU250, C2+ (PID1113)mFOLFOXIRI (OXAL85/IRIN130/CFOL200/FU2400)/CETU500, colorect. Ca, C1 (PID1553) -|- C2-8 (PID1541) -|- BEVA5 maint. (PID1543)mFOLFOXIRI (OXAL85/IRIN130/CFOL200/FU2400)/CETU500, colorect. Ca, C1 (PID1553) -|- C2-8 (PID1541) -|- CETU500 maint. (PID1542)MOUNTAINEER: TUCA300/TRAS8, colorect. Ca, C1 (PID2626) -|- TUCA300/TRAS6, C2+ (PID2627)PANAMA Trial AIO KRK 0212: mFOLFOX-6 (OXAL85/CFOL400/FU2400)/PNTM6, colorect. Ca, ind. (PID1989) -|- PNTM6/CFOL400/FU2400, maint. (PID1988)PERT840/TRAS8, colorect. Ca, C1 (PID1533) -|- PERT420/TRAS6, C2+ (PID1534)TRIBE: FOLFOXIRI (IRIN165/OXAL85/CFOL200/FU3200)/BEVA5, colorect. Ca (PID453) -|- BEVA5/CFOL200/FU3200 maint. (PID454)ChemotherapyChemo-substanceAdagrasibAfliberceptAtezolizumabAvelumabBevacizumabBinimetinibCapecitabineCetuximabDrug-Eluting BeadsEncorafenibFluorouracilFolinic acidFruquintinibIodixanolIpilimumabIrinotecanLapatinibNaCl 0.9%NivolumabOxaliplatinPanitumumabPembrolizumabPertuzumabRamucirumabRegorafenibSodium FolinateSotorasibTegafurTrastuzumabTrastuzumab DeruxtecanTrifluridineTucatinibVemurafenibChemo-substanceAdagrasibAfliberceptAtezolizumabAvelumabBevacizumabBinimetinibCapecitabineCetuximabDrug-Eluting BeadsEncorafenibFluorouracilFolinic acidFruquintinibIodixanolIpilimumabIrinotecanLapatinibNaCl 0.9%NivolumabOxaliplatinPanitumumabPembrolizumabPertuzumabRamucirumabRegorafenibSodium FolinateSotorasibTegafurTrastuzumabTrastuzumab DeruxtecanTrifluridineTucatinibVemurafenibChemo-substanceAdagrasibAfliberceptAtezolizumabAvelumabBevacizumabBinimetinibCapecitabineCetuximabDrug-Eluting BeadsEncorafenibFluorouracilFolinic acidFruquintinibIodixanolIpilimumabIrinotecanLapatinibNaCl 0.9%NivolumabOxaliplatinPanitumumabPembrolizumabPertuzumabRamucirumabRegorafenibSodium FolinateSotorasibTegafurTrastuzumabTrastuzumab DeruxtecanTrifluridineTucatinibVemurafenibChemo-substanceAdagrasibAfliberceptAtezolizumabAvelumabBevacizumabBinimetinibCapecitabineCetuximabDrug-Eluting BeadsEncorafenibFluorouracilFolinic acidFruquintinibIodixanolIpilimumabIrinotecanLapatinibNaCl 0.9%NivolumabOxaliplatinPanitumumabPembrolizumabPertuzumabRamucirumabRegorafenibSodium FolinateSotorasibTegafurTrastuzumabTrastuzumab DeruxtecanTrifluridineTucatinibVemurafenibNo. Substances123456 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFilgrastimGranisetronHydrocortisoneMinocyclineNaCl 0.9%ParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFilgrastimGranisetronHydrocortisoneMinocyclineNaCl 0.9%ParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFilgrastimGranisetronHydrocortisoneMinocyclineNaCl 0.9%ParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFilgrastimGranisetronHydrocortisoneMinocyclineNaCl 0.9%ParacetamolPegfilgrastimNo. Substances1234567Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityLow doseStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleThird line Therapy phaseInductionMaintenanceneoadjuvantneoadjuvant / adjuvantTherapy intentioncurativecurative or palliativepalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityCholinergic SyndromeColitisConstipationCystitisDehydrationDiarrheaDysphoniaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHemorrhageHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperkalemiaHypertensionHyperthyroidismHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypothyroidismIncrease AminotransferasesIncrease Creatinine PhosphokinaseIncrease in lipaseInfectionsInfusion ReactionLeukopeniaMucositisMyalgiasNail ChangesNauseaNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPancreatitisPneumoniaPneumonitisProteinuriaPruritusPyrexiaQTc Time ExtensionRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorAllegra CJAndré TAndré T Antoniotti C Arnold DAssenat EBaba HBleiberg HBoccia RBokemeyer CBoland PMCassidy JChalabi MCheeseman SCheng ALCremolini CCunningham DDasari Ade Gramont ADepartment of Medical Oncology, Franco-British Institute, GERCOR VELVET trialDouillard JYDucreux MFalcone 2007Folprecht GFuchs, CSFukuoka SGhanipour LGrothey AHaller DGHochster HSIveson TKasper SKoopman MKopetz SKuboki YKuhfahl JKöhne CKöhne C, Metzger RLe DTLenz HLeone FLoupakis FMartín-Martorell PMayer R / Van Cutsem EMeric-Bernstam FModest DModest D.Moosmann NMorton DMunemoto YNapolitano S Ocvirk JOverman MOverman MJPeeters MPorschen RRaghav KRothenberg MLSaltz LBSartore-Bianchi ASchmiegel WSchwartzberg LSeymour MTSiena SSinicrope FASomasundaram AStrickler JHTabernero JTakaoka TTaïeb J TournigandTwelves CVan Cutsem Evan Cutsem EWeh HJWein AYaeger R Yamada YYoshida MDiseaseadjuvante Behandlung des Kolon-Karzinoms, Stadium 2/3, ECOG 0-1Adjuvante Behandlung des Kolon-Karzinoms, Stadium II mit Risikofaktoren, oder Stadium III, ECOG 0-1Erstlinie bei unresektablem, metastasiertem kolorektalen Karzinom, ECOG 0-1Erstlinie bei unresektablem, metastasiertem kolorektalen Karzinom, RAS and BRAF wt, ECOG 0-2Erstlinientherapie fortgeschrittenes kolorektales KarzinomErstlinientherapie met. kolorektales Karzinom, ECOG 0-2fortgeschrittenes, nicht-resezierbares metastasiertes kolorektales Karzinom, Adeno-, ECOG 0-2fortgeschrittenes, wiederkehrendes oder metastasiertes kolorektales Karzinom, ECOG 0-2fortgeschrittenes kolorektales Karzinom, Erstlinie, ECOG 0-2fortgeschrittenes oder metastasiertes AEG, Magen- oder kolorektales Karzinom, refraktär oder intolerant, ECOG 0-1fortgeschrittenes oder metastasiertes kolorektales Karzinom, ECOG 0-2Kolon-Ca (T1-4/N1-2/M0), adjuvantKolon-Ca, T3-4, N0-2, M0Kolon-Ca Std. III, adjuvant, ECOG 0-1Kolonkarzinom, Stadium, II und III, adjuvantKolorekt. Adeno-Ca, metastasiert, Progress unter oder innerhalb von 3 Monaten nach Irinotecan-TherapieKolorektales Adenokarzinom, metastasiert, Erstlinie, ECOG 0-2Kolorektales Adenokarzinom, metastasiert, Rezidiv, ECOG 0-1kolorektales Karzinomkolorektales Karzinom, dMMR, Stadium I-III, ECOG 0Kolorektales Karzinom, metastasiert, nach Versagen von mindestens 2 Standardtherapien, ECOG 0-1Kolorektales Karzinom, metastasiert oder lokal fortgeschritten, inoperabel, KRAS wt, ECOG 0-1kolorektales Karzinom, RAS wild-Typ, Erstlinie, ECOG 0-1kolorektales Karzinom, Stadium III, adjuvantKolorektales Karzinom, Stadium III und dMMRKolorektales Karzinom, Stadium IV, dMMR/MSI, nach Erstlinientherapiekolorektales Karzinom, Stadium IV, MSI-H/dMMR, ECOG 0-1Kolorektales Karzinom mit Lebermetastasen, ECOG 0-3kolorektales Karzinom mit nichtresektablen Metastasen in der Leber (ausschließlich), ECOG 0-1Lokal fortgeschrittenes, nicht resezierbares oder metastasiertes kolorektales Karzinom, MSI-H/dMMR, mindestens 1 Vortherapielinie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes kolorekt. Ca, Progress nach 1 oder 2 Vorbehandlungen, BRAF V600E, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes kolorekt. Ca, Progress nach mindestens 1 Vorbehandlung, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes kolorektales Karzinom, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes kolorektales Karzinom, Her2+, RAS Wild-typ, ECOG 0-2met. kolorektales Karzinom, Drittlinie im met. Std., ECOG 0-2; Fuchs 2007: met. kolorektales Karzinom, Erstlinie im met. Std., ECOG 0-1met. kolorektales Karzinom, EGFR+, Erstlinie im met. Std., ECOG 0-2met. kolorektales Karzinom, EGFR+, Erstlinie im met. Std., ECOG 0-2 met. kolorektales Karzinom, Erstlinie, ECOG 0-1met. kolorektales Karzinom, Erstlinie, ECOG 0-2met. kolorektales Karzinom, Erstlinie, ECOG 0-2, über 70 Jahre nur bei ECOG 0Met. kolorektales Karzinom, Erstlinie, ECOG 0-2, über 70 Jahre nur bei ECOG 0met. kolorektales Karzinom, Erstlinie im met. Stadiummet. kolorektales Karzinom, Erstlinie im met. Std., ECOG 0-1met. kolorektales Karzinom, Erstlinie im met. Std., ECOG 0-2met. kolorektales Karzinom, Erstlinie im met. Std., über 70 Jahre, nicht für oxaliplatin- oder irinotecanbasierte Regime geeignetmet. kolorektales Karzinom, höhere Linie nach Versagen der Standardtherapien im met. Std., ECOG 0-1met. kolorektales Karzinom, Progress nach/unter 5-FU, max. 2 Vortherapien im met. Std., ECOG 0-2met. kolorektales Karzinom, Progress nach/unter 5-FU-basierter Therapie in Erstlinie, ECOG 0-2met. kolorektales Karzinom, Progress nach/unter 5-FU-haltiger Therapiemet. kolorektales Karzinom, Progress nach/unter Oxaliplatin-basiertem Regime, ECOG 0-2met. kolorektales Karzinom, Progress unter/innerhalb 6 Monaten nach 5-FU, Irinotecan und Oxaliplatin, ECOG 0-2, ab Drittliniemetastasiertes, nicht kurativ-resezierbares Kolon- oder Rektum-Ca, ECOG 0-2Metastasiertes, nicht kurativ-resezierbares Kolon- oder Rektum-Ca, ECOG 0-2Metastasiertes, nicht kurativ-resezierbares Kolon- oder Rektum-Ca, mBRAF, ECOG 0-2Metastasiertes, nicht kurativ-resezierbares Kolon- oder Rektum-Ca, nach Monotherapie mit Fluotropyrimidinen, ECOG 0-2Metastasiertes, oder nicht resektables kolorektales Karzinom, BRAF und KRAS Wildtyp, mind. 2 Vortherapien, ECOG 0-1metastasiertes kolorekt. Ca, Progress nach 1 oder 2 Vorbehandlungen, BRAF V600E, ECOG 0-1Metastasiertes kolorektales Adeno-Ca, Erstliniemetastasiertes kolorektales Adenokarzinom, Drittlinie, ECOG 0-2metastasiertes kolorektales Adenokarzinom, ECOG 0-2metastasiertes kolorektales Adenokarzinom, Erstlinie, ECOG 0-1metastasiertes kolorektales Adenokarzinom, KRAS/NRAS Wildtyp, Erstlinie, ECOG 0-1metastasiertes kolorektales Karzinom, dMMR/MSI-H, Erstlinie, ECOG 0-1metastasiertes kolorektales Karzinom, dMMR/MSI-H, Rezidiv, ECOG: 0-1metastasiertes kolorektales Karzinom, dMMR/MSI-H, Rezidivtherapie, ECOG 0-1Metastasiertes kolorektales Karzinom, ECOG 0-2Metastasiertes kolorektales Karzinom, Erstlinie, BRAF V600E, ECOG 0-1metastasiertes kolorektales Karzinom, Erstlinie, BRAF V600E, ECOG 0-1metastasiertes kolorektales Karzinom, Erstlinie, ECOG 0-1metastasiertes kolorektales Karzinom, Erstlinie, ECOG 0-2metastasiertes kolorektales Karzinom, Erstlinie im metastasierten Stadium, ECOG 0-2metastasiertes kolorektales Karzinom, HER2+, Rezidivtherapie, ECOG 0-1Metastasiertes kolorektales Karzinom, MSS, KRAS/NRAS/BRAF Wild-Typ, mind. 1 VortherapieMetastasiertes kolorektales Karzinom, Progress nach 5-FU, Irinotecan, Oxaliplatin und AngiogeneseinhibitorMetastasiertes kolorektales Karzinom, vortherapiertMetastasiertes kolorektales Karzinom, Zweitlinie, ECOG 0-1metastasiertes kolorektales Karzinom in Zweitlinie nach Folfox/Bevacizumab, ECOG 0-1Metastasiertes kolorektales Karzinom mit EGFR Expression, Erstlinie, Karnofsky Status >60%Metastasiertes oder nicht resektables kolorektales Karzinom, BRAF und KRAS Wildtyp, mind. 2 Vortherapien, ECOG 0-1Metastasiertes therapieresistentes Kolonkarzinom, Her2 amplifiziert, ECOG 0-2nichtresektables kolorektales Karzinom, Zweitlinie nach AIO/Oxaliplatin, 18-75 Jahre, ECOG 0-2nicht resezierbares, metastasiertes kolorektales Karzinom, Adeno-, Erstlinie, ECOG 0-1Nicht resezierbares kolorektales Karzinom, Drittlinie, RAS Wildtypnichtresezierbares kolorektales Karzinom, Erstlinie, ECOG 0-2Nicht resezierbares kolorektales Karzinom, Rezidivtherapie, ECOG 0-1Peritonealkarzinose, sekundärVorbehandeltes metastasiertes kolorektales KarzinomOriginAbramson Cancer Center at the University of Pennsylvania, Philadelphia, USAAdamson Cancer Center, Philadelphia, USAArbeitsgemeinschaft Internistische Onkologie (AIO)Asklepios Tumor Centre Hamburg, AK Altona, Hamburg; CIREL studyAssistance Publique-Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France, SAMCO-PRODIGE 54 trialAzienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, ItalyCAC Val dÁurelle, Montpellier, France, ERBIRINOXCancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, ACTS-CC trialCancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, JapanCancer Research UK Clinical Centre in Leeds, Cookridge Hospital, UKCenter for Cancer and Blood Disorders, Bethesda, MDCentre René Gauducheau, St-Herblain, Frankreich; PRIME StudieChibaudel BDana-Faber Cancer Institute, Boston, USA; BICC-C; FIRE-3Dana-Farber Cancer Institute, Boston, RECOURSE Study GroupDepartmentGastroenterological Surgery, Kumamoto University, Japan, SOFT studyDepartment of Gastroenterology and Oncology, Tokushima, JapanDepartment of Haematology and Medical Oncology, Hospital Clınico Universitario, University of Valencia, SpainDepartment of Hematology, Oncology and Tumorimmunology, Charite-Universitätsmedizin Berlin, Panama trial/AIO KRK 0212Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, The Xeloda Colorectal Cancer Study GroupDepartment of Internal Medicine 1, Friedrich-Alexander-University, Erlangen NurembergDepartment of Medical Oncology, Piemonte Oncology Foundation, Candiolo, ItalyDepartment of Oncology, Antwerp University Hospital, Edegem, BelgienDepartment of Oncology and Hematology, Martin-Luther-University Halle-Wittenberg, Halle, AIO study groupDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, BelgienDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgien, VELOURDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgien; FIRE-3 (Zweitliteratur)Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgien; FIRE-3 (Zweitliteratur)Duke University Medical Center, Durham, NC, USA, MOUNTAINEER trialEuropean Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986Fukui-ken Saiseikai Hospital, Japan, SAPPHIRE StudieGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, TRICOLORE trialGlasgow University, Glasgow, SchottlandGroupe Coopérateur Multidisciplinaire en Oncologie; GERCORHospital of the University of Munich, Munich, Germany, VOLFI Study (AIO KRK0109) Institute of Oncology, Ljubljana, SlowenienInstitut Gustave Roussy, Villejuif Cedex, Frankreich; FNCLCC ACCORD 13/0503 StudieInstitut Jules Bordet, Brussels, BelgiumKlinik für Innere Medizin, Bremen, DeutschlandKlinik für Internistische Onkologie und Hämatologie, Krankenhaus Barmherzige Brüder, RegensburgMayo Clinic Rochester, Rochester, MN, Alliance A021502; ATOMIC trialMemorial Sloan Kettering Cancer Center, New York, KEYNOTE-177Memorial Sloan Kettering Cancer Center, New York, KRYSTAL-1 trialMemorial Sloan Kettering Cancer Center, New York, USAMulticenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. MOSAIC StudieNational Cancer Center Hospital East, Kashiwa, Japan, C-TASK FORCE / Sunlight investigatorsNational Cancer Center Hospital East, Kashiwa, Japan, REGONIVO trial, EPOC1603National Cancer Center Hospital East, Kashiwa-shi-Chiba, Japan, CodeBreaK 101 Subprotocol HNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, APEC StudyNetherlands Cancer Institute, Amsterdam, the Netherlands, NICHE-1 studyNew York University Cancer InstituteNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy, Hercales StudieOnkologie 2022 / 2023Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, CAIRORutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, TABAsCO trialService de Médecine Interne-Oncologie, Hôpital Saint-Antoine, Paris, FranceSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA, KEYNOTE-164St James's University Hospital and University of Leeds, Leeds UKThe AIO colorectal study groupThe AVEX Study Investigators; AVEX-StudieThe CORRECT Study Goup; CORRECT StudieThe Gruppo Oncologico Nord Ovest (GONO)The Royal Marsden Hospital, London and Surrey, United KingdomThe Royal Marsden Hospital, London and Surrey, United Kingdom; BOND StudiThe Royal Marsden Hospital, London and Surrey, United Kingdom; BOND StudieThe University of Texas Health Science Center at San Antonio, USAThe University of Texas MD Anderson Cancer Center, Houston, TX, USA, CheckMate 142 trialThe University of Texas MD Anderson Cancer Center, Houston, USA, DESTINY-CRC02The Xeloda in Adjuvant Colon Cancer Therapy Trial investigators, X-ACT StudieUniversita Degli Studi Della Campania Luigi Vanvitelli, Napoli, Italy, VELO trialUniversita degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy, DESTINY-CRC01Universitaria Pisana and Università di Pisa, Pisa, Italien; TRIBE StudieUniversity Hospital, Dresden, GermanyUniversity Hospital Birmingham, Birmingham, United KingdomUniversity Hospital Leuven and KU Leuven, Leuven, Belgium, ANCHOR CRC trialUniversity Hospital of Pisa, Pisa, Italy, AtezoTRIBE trialUniversity Hospitals Leuven and KU Leuven, Leuven, Belgium, TASCO1University of Florida, Division of Hematology and Oncology, Gainsville, Florida, NSABPUniversity of Munich, Klinikum Muenchen-Grosshadern, AIO KRK-0104 trialUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NCUniversity of Southampton, Southampton, United Kingdom, SCOT trialUniversity of Texas, MD Anderson Cancer Center, Houston, USA, SWOG S1406University of Texas MD Anderson Cancer Center, Houston, USA, BREAKWATER TrialUniversity of Texas MD Anderson Cancer Center, Houston, USA, MyPathway trialUniversity of Texas MD Anderson Cancer Center, USA, FRESCO-2 trialUniversitätsklinikum Hamburg -Eppendorf, Deutschland; OPUS StudieUppsala University, Uppsala, SwedenUSC Norris Comprehensive Cancer Center, Los Angeles, CA, CheckMate 142 trialVall d'Hebron University Hospital, BarcelonaVall d´Hebron University Hospital, Barcelona, Spanien, RAISE studyVall d’Hebron University Hospital, BarcelonaVall d’Hebron University Hospital, Barcelona, BEACON TrialWest Clinic Memphis, Texas, PEAK StudieWest German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, CEBIFOX trialProtocols in Revision 128 protocols foundAdagrasib 600 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID2549 V1.0)Adagrasib 600 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID2548 V1.0)Adagrasib 600 / Cetuximab 500, Colorectal Carcinoma, Variant 1, Cycle 2+ (PID2602 V1.0)AIO (Folinic Acid 500 / Fluorouracil 2000) / Irinotecan 80, Colorectal Carcinoma (PID467 V1.1)AIO (Folinic Acid 500 / Fluorouracil 2600) / Bevacizumab 5, Colorectal Carcinoma (PID468 V3.1)AIO (Folinic Acid 500 / Fluorouracil 2600), Colorectal Carcinoma (PID39 V1.2)AIO - Folinic Acid 500 / Fluorouracil 1500 / Irinotecan 80 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID485 V2.1)AIO - Folinic Acid 500 / Fluorouracil 1500 / Irinotecan 80 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID486 V2.1)Atezolizumab 840, Colorectal Carcinoma, adjuvant, cycle 13-25 (PID3004 V1.0)Avelumab 800, Colorectal Carcinoma (PID2412 V1.0)Bevacizumab 7.5 / Irinotecan 150 / Tegafur 25, Colorectal Carcinoma (PID1404 V2.0)Bevacizumab 7.5 / Oxaliplatin 130 / Tegafur 25, Colorectal Carcinoma (PID2177 V2.0)Bevacizumab 7.5 / Tegafur 25, Colorectal Carcinoma (PID2743 V1.0)Capecitabine 1000 / Bevacizumab 7.5, Colorectal Carcinoma (PID438 V1.2)Capecitabine 1000 / Irinotecan 250, Colorectal Carcinoma (PID1743 V1.1)Capecitabine 1000 / Oxaliplatin 130, Colorectal Carcinoma (PID443 V1.2)Capecitabine 1000 / Oxaliplatin 70, colorect. Carcinoma (PID457 V1.1)Capecitabine 1250, Colon Cancer adjuvant (PID463 V1.2)Capecitabine 1250, Colorectal Carcinoma (PID434 V1.2)CapIri (Capecitabine 1000 / Irinotecan 200) / Bevacizumab 7.5, Colorectal Carcinoma (PID447 V1.2)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID1820 V1.1)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1821 V1.1)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Panitumumab 9, Colorectal Carcinoma (PID692 V1.2)CAPOX (Capecitabine 1000 / Oxaliplatin 130), Colon Cancer, adjuvant (PID460 V1.2)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Bevacizumab 7.5, Colorectal Carcinoma (PID444 V1.2)Cetuximab (400/250) / Capecitabine 800 / Irinotecan 200, Colorectal Carcinoma, Cycle 1 (PID1818 V1.1)Cetuximab (400/250) / Irinotecan 350, Colorectal Carcinoma, Cycle 1 (PID425 V1.1)Cetuximab 250 / Capecitabine 800 / Irinotecan 200, Colorectal Carcinoma, Cycle 2+ (PID1819 V1.1)Cetuximab 250 / Irinotecan 350, Colorectal Carcinoma, Cycle 2+ (PID426 V1.1)Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID424 V1.2)Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID423 V1.2)Cetuximab 500 / Irinotecan 180 / Vemurafenib 960, Colorectal Carcinoma (PID1746 V1.0)Cetuximab 500 / Irinotecan 180, Colorectal Carcinoma (PID2908 V1.0)DEB-TACE - Irinotecan 100, Colorectal Carcinoma (PID2877 V1.0)Encorafenib 300 / Binimetinib 45 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID2464 V1.0)Encorafenib 300 / Binimetinib 45 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1407 V1.2)Encorafenib 300 / Binimetinib 45 / Cetuximab 250, Colorectal Carcinoma, Cycle 2-7 (PID2465 V1.0)Encorafenib 300 / Binimetinib 45 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID1406 V1.2)Encorafenib 300 / Binimetinib 45 / Cetuximab 500, Colorectal Carcinoma, Cycle 8+ (PID2466 V1.0)Encorafenib 300 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1606 V1.0)Encorafenib 300 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID1605 V1.0)Encorafenib 300 / Cetuximab 500, Colorectal Carcinoma (PID2911 V1.0)EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)Fluorouracil 2600 / Sodium Folinate 500, Colorectal Carcinoma (PID51 V1.1)FOLFIRI (Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400) / Aflibercept 4, Colorectal Carcinoma (PID439 V1.3)FOLFIRI (Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400) / Bevacizumab 5, Colorectal Carcinoma (PID448 V1.1)FOLFIRI (Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400) / Panitumumab 6, Colorectal Carcinoma (PID440 V1.2)FOLFIRI - Cetuximab 500 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID2912 V1.0)FOLFIRI - Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID449 V1.3)FOLFIRI/CETU - Cetuximab (400/250) / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 1 (PID441 V1.3)FOLFIRI/CETU - Cetuximab 250 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 2+ (PID442 V1.4)Folfiri/Ramucirumab - Ramucirumab 8 / Irinotecan 180/ Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID686 V1.2)FOLFOX-4 (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600) / Bevacizumab 5, Colorectal Carcinoma (PID445 V1.1)FOLFOX-4 (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600) / Panitumumab 6, Colorectal Carcinoma (PID450 V1.1)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colon Cancer, adjuvant (PID462 V1.2)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colorectal Carcinoma (PID60 V1.1)FOLFOX-4/CETU - Cetuximab (400/250) / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colorectal Carcinoma, Cycle 1 (PID451 V1.2)FOLFOX-4/CETU - Cetuximab 250 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colorectal Carcinoma, Cycle 2+ (PID452 V1.2)FOLFOX-6 - Cetuximab (400/250) / Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 1 (PID1114 V1.2)FOLFOX-6 - Cetuximab 250 / Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 2+ (PID1178 V1.2)FOLFOX-6 - Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID110 V1.2)FOLFOXIRI (Irinotecan 150, Oxaliplatin 85, Folinic Acid 200, Fluorouracil 3000)/Panitumumab 6, colorect. Ca (PID1413 V1.1)FOLFOXIRI (Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200) / Bevacizumab 5, Colorectal Carcinoma (PID453 V1.1)FOLFOXIRI - Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200 / Atezolizumab 840 / Bevacizumab 5 - Atezolizumab 840 / Bevacizumab 5 / Folinic Acid 200 / Fluorouracil 3200, Colorectal Carcinoma, Maintenance (PID2673 V1.0)FOLFOXIRI - Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200 / Atezolizumab 840 / Bevacizumab 5, Colorectal Carcinoma (PID2672 V1.0)FOLFOXIRI - Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200, Colorectal Carcinoma (PID455 V1.2)FOLFOXIRI/BEVA5 - Bevacizumab 5 / Folinic Acid 200 / Fluorouracil 3200, Colorectal Carcinoma, Maintenance (PID454 V1.2)FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 180 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID687 V1.3)FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 180 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID688 V1.4)Folinic Acid 350 / Fluorouracil 2800, Colorectal Carcinoma (PID2175 V1.0)Fruquintinib 5, Colorectal Carcinoma (PID2560 V1.0)FUFOX - Oxaliplatin 50 / Folinic Acid 500 / Fluorouracil 2000, Colorectal Carcinoma (PID456 V1.2)FUFOX/CETU - Oxaliplatin 50 / Folinic Acid 500 / Fluorouracil 2000 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID483 V2.2)FUFOX/CETU - Oxaliplatin 50 / Folinic Acid 500 / Fluorouracil 2000 / Cetuximab 250, Colorectal Carcinoma, Cycle 2 (PID484 V2.2)Irinotecan 125, Colorectal Carcinoma (PID437 V1.0)Irinotecan 350, Colorectal Carcinoma (PID436 V1.0)Irinotecan 80 / Sodium Folinate 500 / Fluorouracil 2000, Colorectal Carcinoma (PID1157 V1.1)IROX - Irinotecan 200 / Oxaliplatin 85, Colorectal Carcinoma (PID2909 V1.0)mFOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Atezolizumab 840, Colorectal Carcinoma, adjuvant, Cycle 1-12 (PID3003 V1.0)mFOLFOX-6 - Panitumumab 6 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 - Panitumumab 6 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, maintenance (PID1988 V1.0)mFOLFOX-7 - Aflibercept 4 / Folinic Acid 400 / Fluorouracil 3000, Colorectal Carcinoma, maintenance (PID1917 V1.0)mFOLFOX-7 - Aflibercept 4 / Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 3000, Colorectal Carcinoma (PID1916 V1.0)Modified CAPIRI (Capecitabine 800 / Irinotecan 200) / Bevacizumab 7.5, Colorectal Carcinoma (PID446 V1.2)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400) / Bevacizumab 5, Colorectal Carcinoma (PID26 V1.3)Modified FOLFOX-6 - Cetuximab 500 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID2907 V1.0)modified FOLFOX-6 - Oxaliplatin 68 / Folinic Acid 350 / Fluorouracil 1920, Colorectal Carcinoma (PID1084 V1.0)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Colon Cancer, perioperative (PID2257 V1.0)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Colorectal Carcinoma (PID840 V1.1)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID1112 V1.2)Modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 / Cetuximab 500 / Encorafenib 300, Colorectal Carcinoma (PID2910 V1.1)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, colon carcinoma adjuvant (PID644 V1.1)modified FOLFOX-6 - Panitumumab 6 / Oxaliplain 85 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID96 V1.2)modified FOLFOX-6/CETU - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1113 V1.2)modified FOLFOX-6/PNTM - Panitumumab 6 / Oxaliplain 85 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Induction, Var. 1. (PID1989 V1.1)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Folinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500 - Bevacizumab 5 maintenance, Colorectal Carcinoma (PID1543 V1.0)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500 - Cetuximab 500 maintenance, Colorectal Carcinoma (PID1542 V1.0)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500, Colorectal Carcinoma, Cycle 1 (PID1553 V1.0)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500, Colorectal Carcinoma, Cycle 2-8 (PID1541 V1.0)Nivolumab 240 / Ipilimumab 1 / Panitumumab 6, Colorectal Carcinoma (PID3172 V1.0)Nivolumab 240 / Regorafenib 80, Adenocarcinoma Esophagogastric junction, Gastric and Colorectal Carcinoma (PID580 V1.1)Nivolumab 240, Colorectal Carcinoma (PID1234 V2.0)Nivolumab 3 / Ipilimumab 1, Colorectal Carcinoma, first-line (PID2011 V1.0)Nivolumab 3 / Ipilimumab 1, Colorectal Carcinoma, neoadjuvant (PID2328 V1.0)Nivolumab 3 / Ipilimumab 1, Colorectal Carcinoma, Second Line (PID1386 V1.2)Oxaliplatin 100 / Sodium Folinate 400 / Fluorouracil 2400, Colorectal Carcinoma (PID1175 V1.1)Panitumumab 6 / Folinic Acid 200 / Fluorouracil 2400, Colorectal Carcinoma (PID1416 V1.0)Panitumumab 6 / Irinotecan 100 / Tegafur 25, Colorectal Carcinoma (PID2770 V1.1)Panitumumab 6 / Sotorasib 960, Colorectal Carcinoma (PID2205 V1.1)Panitumumab 6, Colorectal Carcinoma (PID435 V1.1)Pembrolizumab 200, Colorectal Carcinoma (PID1517 V1.0)Pembrolizumab 200, Colorectal Carcinoma, First Line (PID1675 V1.0)Pertuzumab 420 / Trastuzumab 6, Tumor Biomarker Defined, Cycle 2+ (PID1534 V1.1)Pertuzumab 840 / Trastuzumab 8, Tumor Biomarker Defined, Cycle 1 (PID1533 V1.1)Regorafenib 160, Colorectal Carcinoma (PID459 V1.0)SCOT - CAPOX (Capecitabine 1000 / Oxaliplatin 130), colon cancer adjuvant, variant 1 (PID3156 V1.0)SCOT - modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Colon Cancer, adjuvant, Variant 1 (PID3155 V1.0)Tegafur 30, Colon Cancer, adjuvant (PID2176 V2.0)Trastuzumab 2 / Lapatinib 1000, Colorectal Carcinoma, Cycle 2+ (PID1155 V1.0)Trastuzumab 4 / Lapatinib 1000, Colorectal Carcinoma, Cycle 1 (PID72 V1.0)Trastuzumab Deruxtecan 5,4, Colorectal Carcinoma (PID2807 V1.0)Trastuzumab Deruxtecan 6.4, Colorectal Carcinoma (PID2357 V1.1)Trifluridine 25 / Irinotecan 180 / Bevacizumab 5, Colorectal Carcinoma (PID2758 V1.0)Trifluridine 35 / Bevacizumab 5, Colorectal Carcinoma (PID1641 V1.1)Trifluridine 35 / Bevacizumab 5, Colorectal Carcinoma, second line (PID1210 V1.2)Trifluridine 35 / Panitumumab 6, Colorectal Carcinoma (PID2358 V1.1)Trifluridine 35, Colorectal Carcinoma (PID843 V2.2)Tucatinib 300 / Trastuzumab 6, Colorectal Carcinoma, Cycle 2+ (PID2627 V1.0)Tucatinib 300 / Trastuzumab 8, Colorectal Carcinoma, Cycle 1 (PID2626 V1.0)
